Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tumor Proliferation Gene Identified

By Biotechdaily staff writers
Posted on 12 Sep 2002
Researchers have found that B-catenin activates the Nr-CAM gene, a gene that was thought to be expressed only in brain cells but is actually overexpressed in several types of cancer. More...
They say the discovery may serve as a foundation for the development of new cancer drugs.

Introduction of Nr-CAM into cells that do not normally express this gene resulted in the enhanced ability of the cells to move spontaneously, and an improved ability to close artificial wounds, but also demonstrated a dangerous tendency for the cells to multiply rather than to stop proliferating. In addition, cells expressing Nr-CAM gained a new capacity to form tumors when injected into lab animals.

The investigators from the Weizmann Institute of Science (Rehovot, Israel) screened various types of cancers for evidence of Nr-CAM overexpression. They found that melanoma cells expressed a great deal of Nr-CAM, and that the quantity of Nr-CAM present in the cells correlated with the stage of the cancer's development.

The researchers injected human melanoma cells displaying different levels of Nr-CAM into mice and found a clear correlation between the presence of the protein and the ability to form rapidly growing tumors. In addition, they were able to arrest the movement of melanoma cells in culture by adding an antibody that blocked the extracellular portion of the Nr-CAM molecule.

From these data, Professor Avri Ben-Ze'ev, of the Weizmann Institute's department of molecular cell biology, concluded that Nr-CAM, a molecule not previously known to play a role in the development of cancer, is a target gene induced by B-catenin to promote uncontrolled cell proliferation.

"Since B-catenin is hyperactive to different degrees in almost every type of cancer, the discovery of Nr-CAM as a target for suppressing these cancers is very promising,” Professor Ben-Ze'ev said. "We were especially excited when we could demonstrate its potential relevance to some of the most prevalent types of cancer in the Western world--melanoma and colon carcinoma.”




Related Links:
Weizmann Inst.

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.